Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Kristin Agopian, PhD

Title(s)Assistant Director, Innovation Ventures
SchoolChancellor/EVC/FAS
Address490 Illinois Street, #4228
San Francisco CA 94158
Phone415-340-2619
PronounsShe/Her/Hers
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Kristin has been commercializing UCSF innovations since 2008 and serves as head of the Licensing Team within Innovation Ventures. In this role, she leads the strategy and execution of technology licensing to both UCSF startups and established life sciences companies, while advancing company formation around breakthrough discoveries. She partners closely with inventors to shape commercialization pathways that maximize translational impact, market potential, and patient benefit across a portfolio spanning therapeutics, diagnostics, and medical devices.

    She earned her Ph.D. in Virology from Harvard University and her A.B. in Molecular Biology from Princeton University. Prior to UCSF, she worked in biotechnology and pharmaceutical strategy consulting and contributed to science and technology policy at the National Academies.

    Kristin is committed to advancing innovation at the interface of science and business, building enduring, mutually beneficial partnerships, and improving patients’ lives.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Proteomic analysis of HIV-1 Nef cellular binding partners reveals a role for exocyst complex proteins in mediating enhancement of intercellular nanotube formation. Retrovirology. 2012 Jun 22; 9:33. Mukerji J, Olivieri KC, Misra V, Agopian KA, Gabuzda D. PMID: 22534017; PMCID: PMC3382630.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    2. Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retroviruses. 2010 Apr; 26(4):495-500. Olivieri KC, Agopian KA, Mukerji J, Gabuzda D. PMID: 20377428; PMCID: PMC2933169.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    3. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology. 2007 May 25; 362(1):163-78. Gorry PR, Dunfee RL, Mefford ME, Kunstman K, Morgan T, Moore JP, Mascola JR, Agopian K, Holm GH, Mehle A, Taylor J, Farzan M, Wang H, Ellery P, Willey SJ, Clapham PR, Wolinsky SM, Crowe SM, Gabuzda D. PMID: 17239419; PMCID: PMC1973138.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    4. CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable. Virology. 2007 Feb 05; 358(1):119-35. Agopian K, Wei BL, Garcia JV, Gabuzda D. PMID: 16979207; PMCID: PMC1995023.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    5. A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2. J Virol. 2006 Mar; 80(6):3050-61. Agopian K, Wei BL, Garcia JV, Gabuzda D. PMID: 16501114; PMCID: PMC1395437.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells